Evaluation of post—cardiopulmonary bypass sonoclot signatures in patients taking nonsteroidal anti-inflammatory drugs

Stern, Mont P.; DeVos-Doyle, Katharina; Viguera, Marcos G.; Lajos, Thomas Z.

doi:10.1016/s0888-6296(89)94843-6

Cited by 17 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like the standard TEG, the Sonoclot is not specific for platelet function, being influenced to a large extent by fibrin formation. It is also insensitive to the effects of aspirin and other NSAIDS 41,42 . Horlocker et al found that the Sonoclot was influenced also by patient age, gender and haematocrit 43 .…”

Section: Sonoclot ®mentioning

confidence: 99%

Point-of-Care Assessment of Antiplatelet Agents in the Perioperative Period: A Review

Gibbs

2009

Anaesth Intensive Care

View full text Add to dashboard Cite

The aim of this paper was to review the strengths and limitations of current 'point-of-care' techniques for the detection of antiplatelet drug effects. The review was based on a Medline search for articles with key words related to "platelet function tests", "point-of-care", and "anaesthesia", published in English between January 1996 and September 2008. It was found that global assessments of 'haemostasis', such as the standard thrombelastograph ® , Sonoclot ® , Clot Signature Analyser ® and Hemodyne™, are not specific for platelet function and are essentially insensitive to cyclooxygenase inhibitors (aspirin, non-steroidal anti-inflammatory drugs) and P 2 Y 12 antagonists (ticlopidine, clopidogrel). Global assessments of 'platelet function', such as the PFA-100 ® and PlateletWorks ® , are more specific for platelet function, but also have limited sensitivity for cyclooxygenase inhibitors and P 2 Y 12 antagonists. The newer devices developed specifically for the assessment of antiplatelet drugs, such as Platelet Mapping ® , the Impact™ Cone and Platelet Analyser and the VerifyNow ® , are more promising, but are not as sensitive as laboratory platelet aggregometry. All three categories of devices detect G p II b /III a antagonists (abciximab, tirofiban, eptifibatide) activity, but not all provide quantitative assessments for monitoring therapy. The limitations appeared to be related to the complexity of platelet function, the multiple pathways of platelet activation, the wide interpatient variability in platelet responses and the interdependence between platelets and other aspects of coagulation. The strengths and limitations of point-of-care devices should be appreciated before they are used to assist clinical decision-making in the perioperative period.

show abstract

Section: Sonoclot ®mentioning

confidence: 99%

Point-of-Care Assessment of Antiplatelet Agents in the Perioperative Period: A Review

Gibbs

2009

Anaesth Intensive Care

View full text Add to dashboard Cite

show abstract

“…Sonoclot coagulation analysis enables bedside determination of clot strength and function in a timely fashion. Several investigators have reported that the Sonoclot Analyzer is useful in predicting postoperative coagulation defects after CPB [17][18][19]. Tuman et al [17] reported that Sonoclot analysis can be a reliable predictor of abnormal clinical hemostasis after CPB.…”

Section: Discussionmentioning

confidence: 99%

“…Tuman et al [17] reported that Sonoclot analysis can be a reliable predictor of abnormal clinical hemostasis after CPB. Stern et al [18] assessed platelet function by the Sonoclot parameter of the clot retraction rate in cardiac surgery patients taking nonsteroidal anti-infl ammatory drugs. Miyashita and Kuro [19] reported that time to peak for the Sonoclot signature can predict approximate platelet function in cardiac surgery.…”

Section: Discussionmentioning

confidence: 99%

Impact of Sonoclot hemostasis analysis after cardiopulmonary bypass on postoperative hemorrhage in cardiac surgery

et al. 2007

View full text Add to dashboard Cite

show abstract

“…It showed a prolonged clot retraction time in patients who had taken NSAIDs prior to cardiopulmonary bypass compared with controls who had not taken NSAIDS, but values obtained from the NSAID group were still within the normal range [50]. Uremic patients had Sonoclot characteristics that appear hypercoagulable [51].…”

Section: Sonoclotmentioning

confidence: 99%

Clinical Utility of Available Methods for Determining Platelet Function

et al. 1999

View full text Add to dashboard Cite

Determination of platelet function has become increasingly important as new antiplatelet drugs are being developed. Objective means to monitor the pharmacological effects of these agents, in order to maximize efficacy and minimize toxicity, is needed. The available methods for determination of platelet function at the current time are reviewed, including platelet aggregometry, the PFA-100, flow cytometry, platelet contractile force, the rapid platelet function assay, the clot signature analyzer, Sonoclot, and thromboelastography. The principle, advantages, disadvantages, and clinical utility of each method is presented. The uses of the various methods of determining platelet function reported in the literature are summarized, in an effort to provide information regarding the applicability of those different methods.

show abstract

Evaluation of post—cardiopulmonary bypass sonoclot signatures in patients taking nonsteroidal anti-inflammatory drugs

Cited by 17 publications

References 5 publications

Point-of-Care Assessment of Antiplatelet Agents in the Perioperative Period: A Review

Point-of-Care Assessment of Antiplatelet Agents in the Perioperative Period: A Review

Impact of Sonoclot hemostasis analysis after cardiopulmonary bypass on postoperative hemorrhage in cardiac surgery

Clinical Utility of Available Methods for Determining Platelet Function

Contact Info

Product

Resources

About